Transplantační medicína

People with type 2 diabetes and atherosclerotic cardiovascular disease face a high risk of cardiovascular events, yet many remain undertreated.¹ The EASD/ADA 2022 and ESC 2023 guidelines for the management of type 2 diabetes urge early insulin initiation and intensive lipid lowering through a holistic approach. Managing both glycemia and lipids together is key to preventing CV events in people with type 2 diabetes.^2,3

People with type 2 diabetes and atherosclerotic cardiovascular disease face a high risk of cardiovascular events, yet many remain undertreated.¹ The EASD/ADA 2022 and ESC 2023 guidelines for the management of type 2 diabetes urge early insulin initiation and intensive lipid lowering through a holistic approach. Managing both glycemia and lipids together is key to preventing CV events in people with type 2 diabetes.^2,3

People with type 2 diabetes and atherosclerotic cardiovascular disease face a high risk of cardiovascular events, yet many remain undertreated.¹ The EASD/ADA 2022 and ESC 2023 guidelines for the management of type 2 diabetes urge early insulin initiation and intensive lipid lowering through a holistic approach. Managing both glycemia and lipids together is key to preventing CV events in people with type 2 diabetes.^2,3

People with type 2 diabetes and atherosclerotic cardiovascular disease face a high risk of cardiovascular events, yet many remain undertreated.¹ The EASD/ADA 2022 and ESC 2023 guidelines for the management of type 2 diabetes urge early insulin initiation and intensive lipid lowering through a holistic approach. Managing both glycemia and lipids together is key to preventing CV events in people with type 2 diabetes.^2,3

In Vietnam, annual influenza hospitalizations among the elderly are 154% higher, and mortality rates 700% higher than in adults aged 50-64. Yet vaccination coverage in those 65 and older remains just 5.55%, well below the WHO target of 75%.

This poster presentation evaluates the efficacy of dupilumab in treating eosinophilic esophagitis (EoE) in patients weighing ≥15 kg at baseline from the Phase 3 KIDS study.

Study Overview: The analysis examines dupilumab efficacy stratified by previous treatment history, including:

- Prior or current use of swallowed topical corticosteroids (STCs) 
- Concomitant proton pump inhibitor (PPI) treatment 
- History of food elimination diet

This poster presentation evaluates the efficacy of dupilumab in treating eosinophilic esophagitis (EoE) in patients weighing ≥15 kg at baseline from the Phase 3 KIDS study.

Study Overview: The analysis examines dupilumab efficacy stratified by previous treatment history, including:

- Prior or current use of swallowed topical corticosteroids (STCs) 
- Concomitant proton pump inhibitor (PPI) treatment 
- History of food elimination diet

This poster presentation evaluates the efficacy of dupilumab in treating eosinophilic esophagitis (EoE) in patients weighing ≥15 kg at baseline from the Phase 3 KIDS study.

Study Overview: The analysis examines dupilumab efficacy stratified by previous treatment history, including:

- Prior or current use of swallowed topical corticosteroids (STCs) 
- Concomitant proton pump inhibitor (PPI) treatment 
- History of food elimination diet

This poster presentation evaluates the efficacy of dupilumab in treating eosinophilic esophagitis (EoE) in patients weighing ≥15 kg at baseline from the Phase 3 KIDS study.

Study Overview: The analysis examines dupilumab efficacy stratified by previous treatment history, including:

- Prior or current use of swallowed topical corticosteroids (STCs) 
- Concomitant proton pump inhibitor (PPI) treatment 
- History of food elimination diet

Older adults are most vulnerable to severe influenza outcomes due to aging immune response, frailty, and comorbidities. Flu Infection worsens chronic conditions, raising risks of hospitalization and death. Influenza vaccination should be part of standard care for the elderly, especially those with chronic diseases.